Preliminary pharmacokinetics of PEGylated oxaliplatin polylactic acid nanoparticles in rabbits and tumor-bearing mice.
To testify the targeting effect of PEGylated Oxaliplatin polylactic acid (OP-PEG-PLA) nanoparticles (NPs), we studied drug concentration in rabbit plasma and tissue distribution in tumor-bearing mice. Concentration of nanoparticle colloidal solution was performed with dialysis. Qualities of enriched NPs were characterized by particle size and drug content. OP concentration in samples was detected using ICP-MS. Compared to OP solution groups, OP concentration of NPs groups increased in the tumor (p < 0.05) and decreased in the kidney and heart (p < 0.05). Compared to OP-PLA NPs groups, OP concentration of OP-PEG-PLA NPs groups increased in the tumor and decreased in the liver and lung (p < 0.05). The concentrated OP-PEG-PLA NPs are good in clinical application and tumor delivery.